CYNBIOSE
Votre contact :
CONTAMIN Hugues
CEO
06 62 74 35 66
Activités :
Cynbiose is a specialty CRO unique in Europe. The company is specialized in preclinical research services with a core expertise and focus on the non-human primate (NHP) model.
We provide hybrid exploratory designs, customized & high value-added services in a high quality-based GLP-like environment.
Our preclinical offer covers:
- Exploratory pharmacokinetics, central PK and pharmacodynamics studies
- Early safety studies, toxicokinetics and biodistribution studies
- Efficacy studies (PoC) in multiple therapeutic areas such as infectious and respiratory diseases, Central Nervous System, immune and inflammation disorders, ...
Our subsidiary, Cynbiose Respiratory, is a preclinical CRO specializing in respiratory diseases and aerosol therapies.
Our facility is AAALAC accredited since 2015 and we can operate studies from BSL 1 to 3. We have also developed unique capabilities in performing studies with ATMPs such as gene therapies containing GMOs (viral vectors, …).
Cynbiose is involved in several collaborative research projects with leading academic research teams and biopharmas, to develop new preclinical models and support progress in biomedical science.
Cynbiose also launched CYNBIOME, the 1st preclinical excellence network on microbiota and infectious diseases based on the Non-Human Primate (NHP) model.
Informations métier
Service(s)
- DMPK
- DMPK
- Pharmacodynamics
- Pharmacodynamique
- Pharmacologie
- Pharmacologie de sécurité
- Pharmacology
- Safety pharmacology
- Toxicologie / Toxicité
- Toxicology / Toxicity
Catégorie(s)
- Anti infectious
- Anti-corps MOA (mode d’action)
- Anti-infectieux
- Anti-infectuous vaccines
- Antibody MOA (mode of action)
- Biodistribution studies
- Biomarkers
- Biomarqueurs
- Bone and cartilage
- Cardiovascular diseases
- CNS
- CNS
- Découverte et analyse des biomarqueurs pour les essais cliniques
- Diabètes
- Diabetes
- Discovery and analysis of biomarkers for clinical trials
- DMPK
- DMPK
- Douleur et maladie inflammatoire
- Études de biodistribution
- Études/efficaces os et cartilage
- Gastro enterology
- Gastro-entérologie
- Immuno inflammation
- Immuno-inflammation
- Immunologie
- Immunology
- Immunotoxicité
- Immunotoxicity
- In-vivo models
- Infectious diseases
- Inflammation
- Inflammation
- Inflammatory diseases
- Liver toxicity
- Maladie métabolique
- Maladie neurodégénérative
- Maladie respiratoire
- Maladies cardiovasculaires
- Maladies infectieuses
- Maladies infectieuses
- Maladies métaboliques et cardiovasculaires
- Metabolic and cardiovascular diseases
- Metabolic disease
- Metabolic diseases models
- Metabolic disesase
- Metabolic disesase
- Metabolic disorders
- Modèles de maladies métaboliques
- Modèles in vivo
- Modèles précliniques
- Monkey
- Multi indications
- Multi-indications
- Neurodegenerative disease
- Neurologie
- Neurology
- Oncologie
- Oncology
- Pain and inflammation disease
- Pharmacocinétique
- Pharmacokinetics
- Pharmacologie
- Pharmacology
- PK – PD
- PK-PD
- Preclinical
- Preclinical consulting services
- Preclinical models
- Preclinical safety
- Préclinique
- Preliminary toxicology
- Respiratory disease
- Rhumatologie
- Rhumatology
- Sécurité préclinique
- Services de consultation préclinique
- Singe
- Therapeutic efficacy validation
- ToxicoKinetics
- ToxicoKinetics
- Toxicologie / toxicité / foie
- Toxicologie préliminaire
- Troubles métaboliques
- Vaccins anti-infectueux
- Validation de l’efficacité thérapeutique
Norme(s)
- AAALAC
- AAALAC
- CIR
- CIR
- GLP
- GLP
Innovation(s) Produit)
«
En cas d'erreur ou d'information incomplète, connectez-vous à votre compte membre, rubrique Mon profil CARTO
Ou en nous contactant à cartographie@afssi.fr. »